HER-2-Positive Tumors: A Continuously Evolving Field in Cancer Research

Ralf Hofheinz; Sylvie Lorenzen; Michael K. Bohlmann

doi:10.3390/cancers15133333

Cancers (Jun 2023)

HER-2-Positive Tumors: A Continuously Evolving Field in Cancer Research

Ralf Hofheinz,
Sylvie Lorenzen,
Michael K. Bohlmann

Affiliations

Ralf Hofheinz: Mannheim Cancer Center, University Hospital Mannheim, University of Heidelberg, 68167 Mannheim, Germany
Sylvie Lorenzen: Klinik und Poliklinik für Innere Medizin III, Technische Universität München, 81675 München, Germany
Michael K. Bohlmann: Zentrum für Geburtshilfe und Gynäkologie, St. Elisabethen Krankenhaus Lörrach, 79539 Lörrach, Germany

DOI: https://doi.org/10.3390/cancers15133333
Journal volume & issue: Vol. 15, no. 13
p. 3333

Abstract

Read online

Almost 25 years ago, trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), was licensed for the treatment of patients with metastatic HER2-positive breast cancer in the United States of America (USA) [...]

n/a

Published in Cancers

ISSN: 2072-6694 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/cancers/

About the journal

Abstract

Keywords